Immutep Ltd.

Plus: Axsome taps investors for $225M, and updates from Immutep, K36, Pfizer, Zai Lab and more

Plus: Rectify hires Minegishi and updates from Epsilogen, Novo and more

Plus CEO named at Prolifagen, and updates from Endpoint, Veracyte, Vyriad and more

Plus DBV meets in peanut-allergic toddlers and updates from Immatics, Edits, Acelyrin and more

Plus Akebia dips after FDA issues CRL for vadadustat, and updates from IGM, Adagio and more

Sydney biotech is readying Phase III in breast cancer as predefined subgroups for eftilagimod deliver

A crop of readouts from compounds against LAG3 strengthen the case for the next-generation checkpoint target

BMS shares the first pivotal efficacy data for a next-generation checkpoint inhibitor

Data being presented at ASCO will make LAG3 the fourth T cell checkpoint target to demonstrate efficacy in a pivotal trial to treat cancer, behind PD-1, PD-L1 and CTLA-4, and companies are piling in.

BMS continued its successful run in checkpoint inhibitors with the first example of a Phase III survival benefit among mAbs against next-generation targets, but it will be hard to determine where the